TY - JOUR
T1 - Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer
AU - Kreuziger, Lisa Baumann
AU - Streiff, Michael
N1 - Funding Information:
Conflict-of-interest disclosure: L.B.K. declares no competing financial interests. M.S. has received research funding from Janssen, Portola, Roche, and PCORI and has consulted for Bio2Medical, Janssen, CSL Behring, and Merck.
PY - 2016
Y1 - 2016
N2 - A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?
AB - A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?
UR - http://www.scopus.com/inward/record.url?scp=85020374411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020374411&partnerID=8YFLogxK
U2 - 10.1182/asheducation-2016.1.206
DO - 10.1182/asheducation-2016.1.206
M3 - Article
C2 - 27913481
AN - SCOPUS:85020374411
SN - 1520-4391
VL - 2016
SP - 206
EP - 207
JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
IS - 1
ER -